Physician profile
Wayne G Shen
NPI 1972541258
$5,493.85
in general payments reported to CMS, 2019-2025
31 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,912 · 2020: $116 · 2021: $112 · 2022: $545 · 2023: $572 · 2024: $1,093 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,808.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $1,483.28 | 2019-2024 | Rytary |
| Abbvie INC. | $1,189.64 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Pfizer INC. | $441.30 | 2023-2025 | |
| Sk Life Science, INC. | $348.53 | 2024-2025 | |
| Glaxosmithkline, LLC. | $295.02 | 2020-2025 | Nucala |
| Ucb, INC. | $262.80 | 2019-2025 | Briviact |
| Boston Scientific Corporation | $147.12 | 2024-2025 | Watchman Flx, General - Dbs |
| Astrazeneca Pharmaceuticals LP | $145.89 | 2019-2023 | Andexxa |
| Eisai INC. | $145.82 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $118.80 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.84 | 2022 | |
| Acorda Therapeutics, INC | $93.76 | 2019 | |
| Genzyme Corporation | $83.85 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $81.67 | 2022-2023 | Austedo |
| Portola Pharmaceuticals, LLC | $60.69 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $49.16 | 2019 | |
| Philips North America LLC | $45.67 | 2019 | |
| Livanova USA, INC. | $39.64 | 2019-2020 | |
| Biogen, INC. | $38.79 | 2024 | Vumerity, Tysabri |
| Genentech USA, INC. | $33.30 | 2025 | Ocrevus Zunovo |
| Kyowa Kirin, INC. | $32.70 | 2023-2024 | Nourianz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.78 | 2019-2020 | |
| Amgen INC. | $30.74 | 2020 | |
| Adamas Pharmaceuticals, INC. | $29.54 | 2019 | |
| Lundbeck LLC | $27.08 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $26.22 | 2021 | |
| Avanir Pharmaceuticals, INC. | $24.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.98 | 2019 | |
| Allergan, INC. | $20.43 | 2020 | |
| Argenx US, INC. | $14.24 | 2023 | Vyvgart |
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.